CD8A and rhabdomyosarcoma: Subsequently, we administered the STAT3 inhibitor Stattic to rhabdomyosarcoma-bearing wild-type mice, and observed a remarkable tumor growth inhibition (Figure 6A), and the frequency of CD8+ as well as CD8+IFN-γ+ T cells in the spleen and lymph nodes were markedly upregulated (Figures 6B, C).